MoonLake Immunotherapeutics

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, MoonLake Immunotherapeutics had 298.49M in cash and cash equivalents.

MoonLake Immunotherapeutics reported 119.95M in total liabilities as of the latest reported quarter, including 45.48M in current liabilities and 74.47M in non-current liabilities.

As of the latest reported quarter, MoonLake Immunotherapeutics's total assets were 424.43M, consisting of 421.69M in current assets and 2.74M in non-current assets.

MoonLake Immunotherapeutics reported 304.48M in total shareholders' equity as of the latest reported quarter.